Bieche We, Parfait B, Tozlu S, Lidereau Roentgen, Vidaud M: Quantitation out-of androgen receptor gene term in the sporadic breast cancers from the real-day RT-PCR: evidence you to MYC try an enthusiastic AR-managed gene. Carcinogenesis. 2001, 22 (9): 1521-1526. /carcin/twenty two.9.1521.

Bratthauer GL, Lininger RA, Son YG, Tavassoli FA: Androgen and the hormone estrogen receptor mRNA standing into the apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.

Gatalica Z: Immunohistochemical investigation from apocrine breast lesions. Uniform more-expression regarding androgen receptor followed closely by the loss of estrogen and you can progesterone receptors inside the apocrine metaplasia and you can apocrine carcinoma inside the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.

Was J Clin Pathol

Soreide JA, Lea OA, Varhaug JE, Skarstein An effective, Kvinnsland S: Androgen receptors during the operable cancer of the breast: regards to most other steroid hormones receptors, correlations so you can prognostic facts and you may predictive worth to have effectation of adjuvant tamoxifen procedures. Eur J Surg Oncol. 1992, 18 (2): 112-118.

Bayer-Garner IB, Smoller B: Androgen receptors: an effective marker to increase sensitiveness to own determining breast cancer within the epidermis metastasis regarding not familiar pri, 13 (2): 119-122. /modpathol.3880021.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and you will clinical ramifications. J Clin Oncol. 2000, 18 (5): 1135-1149.

Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A beneficial: Control out-of matrix metalloproteinase 13 phrase of the androgen for the prostate malignant tumors. Oncol Rep. 2004, eleven (6): 1187-1192.

Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.

Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Research of your own prognostic dependence on androgen receptor expression in the metastatic cancer of the breast. Virchows Arch. 2006, 449 (1): 24-30. /s00428-00six-0213-6.

Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB: Comparison out-of interlaboratory version throughout the immunohistochemical commitment of estrogen receptor position having fun with a cancer of the breast structure microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.

Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Examination of matrix metalloproteinases as well as their inhibitors within the cancer of the breast. Br J Cancers. 2007, 96 (6): 903-911. /sj.bjc.6603666.

Narita D, Raica Yards, Suciu C, Cimpean A good, Anghel An excellent: Immunohistochemical term from androgen receptor and you will prostate-specific antigen inside the cancer of the breast. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.

Egeblad M, Werb Z: The brand new services toward matrix metalloproteinases in cancers advancement. Nat Rev Cancers. 2002, dos (3): 161-174. /nrc745.

Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–for the head stage out of disease?. Cancers Mobile. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.

Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Elizabeth, Martinez Air-con: The fresh matrix metalloproteinase-9 handles the latest insulin-eg gains foundation-caused autocrine response inside DU-145 carcinoma muscle. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..

Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Age, Matrisian LM, Mareel Yards: Launch of an invasion promoter Age-cadherin fragment of the matrilysin and stromelysin-step one. J Mobile Sci. 2001, 114 (Pt step 1): 111-118.

Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] expression chooses to own muscle with reduced sensitivity so you’re able to apoptosis. Neoplasia. 2001, step three (6): 459-468. /sj.neo.7900190.

CO;2-H

Stetler-Stevenson WG: Matrix metalloproteinases for the angiogenesis: a moving address to own therapeutic intervention. J Clin Invest. 1999, 103 (9): 1237-1241. /JCI6870.

Cornelius Los angeles, Nehring LC, Harding E, Şimdi buraya tıklayın Bolanowski Yards, Welgus HG, Kobayashi DK, Penetrate RA, Shapiro SD: Matrix metalloproteinases create angiostatin: effects towards the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.

Jiang Y, Goldberg ID, Shi YE: Cutting-edge spots regarding tissues inhibitors out of metalloproteinases in malignant tumors. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.